Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing since 12/18/2024, newest first.
| Issuer | % of Class | Filed | |||
|---|---|---|---|---|---|
|
Context Therapeutics Inc.
13G/A
Amendment 1
CNTX · 21077P108
|
3.3% |
7/31/2026
Event 6/30/2026
|
|||
| Octagon Capital Advisors LP | 3.3% | ||||
| Octagon Investments Master Fund LP | 3.3% | ||||
| Ting Jia | 3.3% | ||||
|
Gossamer Bio, Inc.
13G/A
Amendment 2
GOSS · 38341P102
|
3.8% |
5/14/2026
Event 3/31/2026
|
|||
| Octagon Capital Advisors LP | 3.8% | ||||
| Octagon Investments Master Fund LP | 3.8% | ||||
| Ting Jia | 3.8% | ||||
|
Dianthus Therapeutics, Inc. /DE/
13G/A
Amendment 3
DNTH · 252828108
|
3.6% |
5/14/2026
Event 3/31/2026
|
|||
| Octagon Capital Advisors LP | 3.6% | ||||
| Octagon Investments Master Fund LP | 3.0% | ||||
| Octagon Biotech Opportunities Fund I LP | 0.6% | ||||
| Ting Jia | 3.6% | ||||
|
Corbus Pharmaceuticals Holdings, Inc.
13G/A
Amendment 2
CRBP · 21833P301
|
0% |
5/14/2026
Event 3/31/2026
|
|||
| Octagon Capital Advisors LP | 0% | ||||
| Octagon Investments Master Fund LP | 0% | ||||
| Ting Jia | 0% | ||||
|
Context Therapeutics Inc.
13G
CNTX · 21077P108
|
5.7% |
5/14/2026
Event 3/31/2026
|
|||
| Octagon Capital Advisors LP | 5.7% | ||||
| Octagon Investments Master Fund LP | 5.7% | ||||
| Ting Jia | 5.7% | ||||
|
Gossamer Bio, Inc.
13G/A
Amendment 1
GOSS · 38341P102
|
6.5% |
2/17/2026
Event 12/31/2025
|
|||
| Octagon Capital Advisors LP | 6.5% | ||||
| Octagon Investments Master Fund LP | 6.5% | ||||
| Ting Jia | 6.5% | ||||
|
Precision BioSciences, Inc.
13G
DTIL · 74019P207
|
10.0% |
2/10/2026
Event 12/31/2025
|
|||
| Octagon Capital Advisors LP | 10.0% | ||||
| Octagon Investments Master Fund LP | 10.0% | ||||
| Ting Jia | 10.0% | ||||
|
Unicycive Therapeutics, Inc.
13G/A
Amendment 3
UNCY · 90466Y202
|
4.7% |
2/10/2026
Event 12/31/2025
|
|||
| Octagon Capital Advisors LP | 4.7% | ||||
| Octagon Investments Master Fund LP | 3.0% | ||||
| Octagon Biotech Opportunities Fund I LP | 1.7% | ||||
| Ting Jia | 4.7% | ||||
|
Corbus Pharmaceuticals Holdings, Inc.
13G/A
Amendment 1
CRBP · 21833P301
|
5.4% |
2/10/2026
Event 12/31/2025
|
|||
| Octagon Capital Advisors LP | 5.4% | ||||
| Octagon Investments Master Fund LP | 5.4% | ||||
| Ting Jia | 5.4% | ||||
|
Palisade Bio, Inc.
13G
PALI · 696389402
|
6.4% |
2/10/2026
Event 12/31/2025
|
|||
| Octagon Capital Advisors LP | 6.4% | ||||
| Octagon Investments Master Fund LP | 6.4% | ||||
| Ting Jia | 6.4% | ||||
|
Unicycive Therapeutics, Inc.
13G/A
Amendment 2
UNCY · 90466Y202
|
5.7% |
11/14/2025
Event 9/30/2025
|
|||
| Octagon Capital Advisors LP | 5.7% | ||||
| Octagon Investments Master Fund LP | 3.7% | ||||
| Octagon Private Opportunities Fund II LP | 2.0% | ||||
| Ting Jia | 5.7% | ||||
|
Taysha Gene Therapies, Inc.
13G/A
Amendment 1
TSHA · 877619106
|
3.3% |
11/14/2025
Event 9/30/2025
|
|||
| Octagon Capital Advisors LP | 3.3% | ||||
| Octagon Investments Master Fund | 3.3% | ||||
| Ting Jia | 3.3% | ||||
|
Dianthus Therapeutics, Inc. /DE/
13G/A
Amendment 2
DNTH · 252828108
|
6.1% |
11/14/2025
Event 9/30/2025
|
|||
| Octagon Capital Advisors LP | 6.1% | ||||
| Octagon Investments Master Fund LP | 5.3% | ||||
| Octagon Private Opportunities Fund II LP | 0.7% | ||||
| Ting Jia | 6.1% | ||||
|
ArriVent BioPharma, Inc.
13G/A
Amendment 1
AVBP · 04272N102
|
4.9% |
11/14/2025
Event 9/30/2025
|
|||
| Octagon Capital Advisors LP | 4.9% | ||||
| Octagon Investments Master Fund LP | 1.9% | ||||
| Octagon Private Opportunities Fund LP | 2.0% | ||||
| Octagon Special Opportunities Fund LP - Series 4 | 1.0% | ||||
| Ting Jia | 4.9% | ||||
|
Unicycive Therapeutics, Inc.
13G/A
Amendment 1
UNCY · 90466Y202
|
7.8% |
8/12/2025
Event 6/30/2025
|
|||
| Octagon Capital Advisors LP | 7.8% | ||||
| Octagon Investments Master Fund LP | 5.1% | ||||
| Octagon Private Opportunities Fund II LP | 2.7% | ||||
| Ting Jia | 7.8% | ||||
|
Gossamer Bio, Inc.
13G
GOSS · 38341P102
|
8.6% |
2/5/2025
Event 12/31/2024
|
|||
| Octagon Capital Advisors LP | 8.6% | ||||
| Octagon Investments Master Fund | 8.6% | ||||
| Ting Jia | 8.6% | ||||
|
Taysha Gene Therapies, Inc.
13G
TSHA · 877619106
|
5.1% |
2/5/2025
Event 12/31/2024
|
|||
| Octagon Capital Advisors LP | 5.1% | ||||
| Octagon Investments Master Fund | 5.1% | ||||
| Ting Jia | 5.1% | ||||
|
Dianthus Therapeutics, Inc. /DE/
13G/A
Amendment 1
DNTH · 252828108
|
7.1% |
2/5/2025
Event 12/31/2024
|
|||
| Octagon Capital Advisors LP | 7.1% | ||||
| Octagon Investments Master Fund LP | 6.1% | ||||
| Octagon Private Opportunities Fund II LP | 1.0% | ||||
| Ting Jia | 7.1% | ||||